Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 139,441 shares of the company's stock after acquiring an additional 16,373 shares during the period. Voya Investment Management LLC owned 0.14% of Neurocrine Biosciences worth $19,034,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of NBIX. Dodge & Cox increased its stake in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after purchasing an additional 1,728,605 shares during the period. Raymond James Financial Inc. acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $115,193,000. Wellington Management Group LLP raised its stake in Neurocrine Biosciences by 102.9% during the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after acquiring an additional 739,199 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock worth $100,705,000 after purchasing an additional 711,970 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock valued at $112,025,000 after purchasing an additional 485,894 shares during the period. Institutional investors own 92.59% of the company's stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,707 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the sale, the director now directly owns 517,030 shares in the company, valued at approximately $79,064,227.60. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67. Following the completion of the transaction, the chief executive officer now owns 136,778 shares in the company, valued at $20,909,252.86. This trade represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,801 shares of company stock worth $2,834,677 over the last three months. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Trading Up 0.9 %

Shares of NASDAQ:NBIX opened at $106.73 on Monday. The firm has a market cap of $10.56 billion, a price-to-earnings ratio of 32.44, a P/E/G ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.98. The business has a fifty day simple moving average of $107.16 and a 200 day simple moving average of $122.22.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its board has initiated a stock repurchase program on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have commented on NBIX. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a "hold" rating and a $138.00 target price on the stock. Bank of America cut their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research report on Friday, February 7th. UBS Group lowered their price target on Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, April 4th. Evercore ISI cut their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday. Finally, Canaccord Genuity Group lowered their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $161.14.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.